So, back to the 4c
As Eddie has pointed out, these revenue numbers are indeed impressive. I have mentioned the growth & trajectory of Creso many times on here over the last couple of years, and the trend continues - rapid and constant.
I called revenue at $A7-8 million for this FY. I'll call it - right here, right now - at $A13-15 mil for CY 2022. And into the 20's for 2023 ......... then there's your 40c share price.
Mernova can EASILY take $A4 mil per quarter in the near term. Their THC brands are definitely gaining traction - with the US still on the horizon. Well done Jack Wu.
CBD/pet products can triple to $A3 mil without much extra input or associated costs - the setups have already been established.
ImpActive is an interesting one. It's the Trojan Horse taking our CBD into the US. Ice Hockey players are big celebrities over there (and they take a beating !) and their endorsement gives Creso's products a significant point of difference. Watch this one grow fast.
This Quarterly represents a cultural change in the attitude of management - it's glaringly obvious. The American's fingerprints are all over this report.
OK bashers - go back to talking about CPH from 2/3 years ago.
- Forums
- ASX - By Stock
- CPH
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-34
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Gold nuggets unearthed at Comet Well ahead of drilling! Discoveries continue as exploration ramps up
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
Add CPH (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online